VivoSeq
Other

Stereotactic Body Radiation Therapy

0

Pipeline Programs↗

2

Active Trials↗

0

Companies Involved↗

Stereotactic Body Radiation Therapy is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

29/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Completed2 · 29%
Terminated2 · 29%
Recruiting1 · 14%
Active, not recruiting1 · 14%
Unknown status1 · 14%

Clinical Trials

Trial Activity

7 trials

Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)
Recruiting·—·Phase 1·NCT05371132·10 enrolled
Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone
Active, not recruiting·—·Phase 2·NCT02880319·150 enrolled
Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers
Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03452332·20 enrolled
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
Completed·—·Phase 1·NCT01652794·12 enrolled
Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer
Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT04220775·3 enrolled
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT04785287·13 enrolled
Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)
Unknown status·CCentre Georges Francois Leclerc·Phase 1·NCT05259319·92 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)